Get started
Adaptimmune Therapeutics plcAA

Adaptimmune Therapeutics plc

0.3150USDR
−0.0089−2.75%
As of today at 13:30 GMT
USD
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

ADAP trade ideas

ADAP - Biotech Catalyst Pre Run Up PlayAdaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types. Upcoming Catalyst: PDUFA priority review PDUFA target action date of August 4, 2024 I expect a pre run up into the catalyst. Holding through the Data release is highly speculative - keep that in mind. Technical Analysis Current Resistance Levels: $1.35 -1.40, 1.65 Target Price (Take Profit): $1.80 Stop Loss: Set at under $0.95 Trading Strategy Entry Point: Monitor the critical range of $1.35 - 1.40 Maybe we see a small pullback to 1.10 zone before continouing the breakout Action: If the stock breaks above this range with strong volume, it might signal a continuation of the upward trend. Profit Target: Set Take Profit at $1.80, considering the recent positive news and technical setup. Risk Management: Stop Loss: Place slightly below $0.95 to protect against significant losses if the stock reverses. Considerations Market Conditions: Overall market conditions can influence the stock's performance. Monitor broader market trends. News Updates: Stay informed about any news related to Adaptimmune Therapeutics Plc ADR, especially regarding FDA approvals, clinical trials, and product launches. Chart Analysis Review the attached chart for detailed price trends and movements. Key Technical Indicators: Pay attention to moving averages, Relative Strength Index (RSI), and Moving Average Convergence Divergence (MACD) for further insights into the stock’s momentum and potential reversals. Trading Advisory Caution: Exercise caution and align your trading actions with your risk tolerance and market conditions. Research: Conduct comprehensive research or consult with a financial advisor to tailor the strategy to your individual circumstances. Disclaimer This content is for informational purposes only and should not be considered financial advice. By following this strategic approach, you can potentially capitalize on the recent positive developments and technical signals for ADAP
NASDAQ:ADAPLong
by meitshels_smell_trades
6
$ADAP is gonna fall todayPupm&Dump trading strategy idea. $ADAP is rising too much today. The demand for shares of the company looks lower than the supply. This and other conditions can cause a fall in the share price today. So I opened a short position from $6,29; stop-loss — $6,52; take-profit — $5,82/MOC Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NShort
by KozakHlib
SPEAR T-cell Platform Delivers Initial Responses in Four Solid TAdaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications -------------------------------------------------------------- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers. -------------------------------------------------------------- Encouraging demonstration of the potential of SPEAR T-cell platform across multiple targets and a range of solid tumors ---------------------------------------------------------- two confirmed Partial Responses (PRs) – one in a patient with liver cancer and one in a patient with melanoma. ---------------------------------------------------------- There are also two unconfirmed PRs – one in a patient with gastro‑esophageal junction cancer and one in a patient with head and neck cancer ---------------------------------------------------------- These data further confirm the potential of Adaptimmune’s SPEAR T-cell platform for patients with multiple solid tumors. ---------------------------------------------------------- These responses demonstrate that our proprietary SPEAR T-cell platform is clearly active and can overcome the challenges of treating a range of solid tumors with a T-cell therapy product- ---------------------------------------------------------- These are early results and we need more patient data and durability information to determine which therapies to develop. www.adaptimmune.com
N
by AlenCiken
SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in EGJIn the Surpass trial, three of the first four patients treated with ADP-A2M4CD8 had smaller tumors at the last checkup than they did at the outset. ---------------------------------------------------------- Eight out of 16 patients with synovial sarcoma have shown partial responses to treatment with ADP-A2M4. --------------------------------------------------------- Two out of three esophagogastric junction (EGJ) cancer patients treated with ADP-A2M4CD8 showed partial tumor shrinkage. --------------------------------------------------------- Also, one out of three liver cancer patients treated with ADP-A2AFP that had a partial response earlier this year has improved to a complete response. This sign of durability was particularly encouraging because this was the first patient treated with this candidate at the target dosage. --------------------------------------------------------- Adaptimmune doesn't have any approved products to sell yet, but new tumor responses reported today suggest the company's headed toward commercialization in more directions than previously expected. Adaptimmune intends to complete the recruitment of synovial sarcoma patients into the Spearhead-1 trial with ADP-A2M4 by the end of June, and based on today's update, the company thinks the trial will support an accelerated approval followed by a commercial launch in 2022. Based on responses from EGJ patients treated with ADP-A2M4CD8 so far, Adaptimmune will start a new phase 2 study focused on this indication. Despite today's big run-up, there could be a lot more room for this stock to climb if its cell-based cancer therapy candidates continue to impress. www.fool.com www.adaptimmune.com
N
by AlenCiken
$ADAP can rise in the next daysContextual immersion trading strategy idea. Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. Friday morning the company presented positive data on its experimental cell therapy, which is designed to treat a range of cancers. It causes a rise in the share price. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price in the next days. So I opened a long position from $11,85; stop-loss — $11,18. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NLong
by KozakHlib
Entry for long positionStrong Fundamental data has created the more recent bullish trend. I have been waiting for a safe entry point for about 2 months now after selling off some profits in the 13s. mid 10s has been my forecast for optimum entry for some time now and it looks like we are just about there. I am thinking that I will phase in throughout this week and set a stop around 9.75. Profit targets are hard to project but my gut tells me somewhere around mid 17s.
NLong
by JasonSpence
Long ADAPI am basing my speculations for this stock purely off my TA. ADAP is showing many indication that the stock is a good pick when Investing long (3 months to 1 year). However i don't think today is the best day to get on the train. I believe that ADAP is slightly overbought at the moment and in the short term, it will correct in price. There will be an opportunity to buy in the next few days. When ADAP was listed on the NASDAQ in late 2015 the stock price dropped to from 20$ to about 4$, loosing 4/5 of its value. From 2017 to the present, ADAP is growing at a steady pace and following a steady trend line up. The crash of ADAP from 2015-16 indicates that this stock has the potential to grow to its previous highs and maybe even then some. If you plan on making a long term position in ADAP, I think buying in the next couple days could put you in a good position. One pattern I recognized on the chart was an inverse triple bottom. Although this is usually a bearish indicator, because the neckline of the Triple bottom is not horizontal, I believe that this indicates a slight correction down to about 10-8$ a share and nothing more. There is too much built up support for ADAP to fall past 8$, and this is why I think 8-10$ is the ideal price to get in on. I hope found found my analysis helpful, please let me know what you think! Thanks, Colm :)
NLong
by CryptoColm
3